Delivery Order SPE2DB22D2007-SPE2DB25FJ3KC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a $5,913.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), with completion targeted for August 26, 2025. This non-set-aside contract represents a single delivery order execution against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $5,357.13 to AmerisourceBergen Drug Corp for Quillivant XR oral suspension (150mL, 5mg/mL) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency awarded a $3,030.27 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml). This is a firm fixed price contract with an ultimate completion date of August 11, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed from the contractor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,859.94 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in a 120 mL container. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) with a ceiling value of $1,731.16. This competitively awarded, non-set-aside contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,314.20 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement with an ultimate completion date of June 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3KCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,509.82 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities. The contract was awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, and represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. Quillivant XR is an extended-release formulation of methylphenidate used to treat attention-deficit/hyperactivity disorder. This delivery order represents one of numerous pharmaceutical and medical supply transactions executed under AmerisourceBergen Drug Corp's DLA prime vendor agreement, which enables the company to supply a broad range of medications, vaccines, and medical devices to support military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The vendor's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical procurement requirements through open competition and flexible contract vehicles designed to support global military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 7/29/25 |